Skip to main contentSkip to navigationSkip to search

Final results of SAS rights issue – oversubscribed by 24.2 percent

April 15, 2009 16:01

According to the final results of SAS AB’s (“SAS”) rights issue, for which the subscription period ended 6 April 2009, 2,293,533,321 shares, corresponding to 99.6 percent of the offered shares were subscribed for with subscription rights. In addition, 566,900,561 shares were subscribed for without subscription rights, corresponding to 24.6 percent of the offered shares. Of the shares subscribed for without subscription rights, 9, 466,679 shares have been allocated to subscribers based on the principles described in the prospectus published on 17 March 2009. Thus, the rights issue was oversubscribed by 24.2 percent and the underwriting commitments did not need to be utilised. Through the rights issue SAS will receive proceeds of up to SEK 6,056,890,000 before transaction costs.

As a result of the rights issue the share capital is expected to be increased by SEK 5,757,500,000 to SEK 6,168,750,000 (after implementation of the share capital reduction resolved by the Extraordinary General Meeting on 13 March 2009 in order to enable and facilitate the rights issue). The number of shares in the company is expected to be increased by 2,303,000,000 shares to 2,467,500,000 shares.

The final day for trading in the BTA 1 is expected to be 17 April 2009. Trading in the new shares subscribed for with subscription rights on NASDAQ OMX Stockholm, NASDAQ OMX Copenhagen and Oslo Børs is expected to commence on 20 April 2009. The first day of trading in the BTA 2 is expected to be 21 April 2009 and the final day of trading in the BTA 2 is expected to be 30 April 2009 on NASDAQ OMX Stockholm and 1 May 2009 on NASDAQ OMX Copenhagen.

For further information, please contact
Sture Stølen, Head of SAS Group Investor Relations, +46 8 797 14 51
SAS Group Investor Relations
This document is not being distributed to persons in any state or jurisdiction where the offer or sale of the Rights or Shares is not permitted.

These materials are not an offer for sale of securities in the United States. Securities may not be sold in the United States absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended. The issuer of the securities does not intend to register any part of the offering in the United States or to conduct a public offering of the Rights or the Shares in the United States.
This document is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons in (i), (ii) and (iii) above together being referred to as “relevant persons”). The Rights and the Shares are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.

This document is an advertisement and is not a prospectus for the purposes of Directive 2003/71/EC (such Directive, together with any applicable implementing measures in the relevant home Member State under such Directive, the “Prospectus Directive”). A prospectus prepared pursuant to the Prospectus Directive will be published, which, when published, can be obtained from the SAS Group. Investors should not subscribe for any securities referred to in this document except on the basis of information contained in the prospectus.

In any EEA Member State that has implemented the Prospective Directive, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Directive.

Latest news